1. < Home

pruritus

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal[...]

By sjmartinez • February 13, 2024
Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study

Veverka KA, Thng STG, Silverberg JI, Armstrong AW, Menezes J, Kaoukhov A, Blauvelt A. Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults[...]

By sjmartinez • October 23, 2023
Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis

Rastogi A, Fishbane S, Lerma E. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. Expert Rev Clin Pharmacol. 2023[...]

By sjmartinez • April 4, 2023
A multicenter descriptive analysis of 270 men with frontal fibrosing alopecia and lichen planopilaris in the United States

Pathoulas JT, Flanagan KE, Walker CJ, Collins MS, Ali S, Pupo Wiss IM, Cotsarelis G, Milbar H, Huang K, Mostaghimi A, Scott D, Han JJ,[...]

By sjmartinez • March 22, 2023